Champions Oncology reports record Q2 revenue of $14.3M, cuts FY growth outlook to 10-15%

CHAMPIONS ONCOLOGY, INC.

2023-Q2 EPS reported -$0.02 revenue$28,026,000

Record quarterly revenue of $14.3M, up 21% YoY from $11.8M.
Adjusted EBITDA of $686K, down from $743K in prior-year period.
Operating income just $7K; gross margin fell to 48% from 52%.
Full-year growth target revised to 10%-15% due to increased cancellations and economic slowdown.
Cash on hand $10.8M, no debt; cash from operations $3.3M for the quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

CHAMPIONS ONCOLOGY, INC. reported second quarter of fiscal 2023, ended October 31, 2022 results: revenue $14.3 million. Guidance lowered.

Period: second quarter of fiscal 2023, ended October 31, 2022
Revenue: $14.3 million
Guidance: lowered
Result: reported results

Exact text from the filing

in such a filing. --- EX-99.1 (EX-99.1) --- NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $14.3 Million Hackensack, NJ – December 13 , 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

CHAMPIONS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001628280-22-031796

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.